Conformis (NASDAQ:CFMS) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Conformis (NASDAQ:CFMSGet Rating) in a report published on Monday. The brokerage issued a hold rating on the medical instruments supplier’s stock.

Other equities research analysts have also issued reports about the company. Oppenheimer increased their price target on Conformis from $1.25 to $8.00 and gave the stock an outperform rating in a research report on Friday, November 11th. Canaccord Genuity Group lowered their target price on Conformis from $2.00 to $1.00 and set a buy rating for the company in a research note on Thursday, August 11th.

Conformis Stock Up 6.7 %

Shares of NASDAQ CFMS opened at $2.06 on Monday. Conformis has a 52-week low of $1.20 and a 52-week high of $24.75. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.04 and a current ratio of 5.07. The business has a fifty day moving average of $0.51 and a two-hundred day moving average of $0.39. The stock has a market cap of $15.49 million, a PE ratio of -0.24 and a beta of 1.14.

Conformis (NASDAQ:CFMSGet Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The medical instruments supplier reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $13.78 million for the quarter, compared to the consensus estimate of $13.89 million. Conformis had a negative net margin of 104.46% and a negative return on equity of 78.14%. As a group, equities research analysts expect that Conformis will post -8.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC bought a new position in Conformis in the 1st quarter valued at $40,000. Jane Street Group LLC bought a new position in Conformis in the second quarter valued at about $84,000. Bank of New York Mellon Corp increased its position in Conformis by 2.3% in the third quarter. Bank of New York Mellon Corp now owns 368,020 shares of the medical instruments supplier’s stock worth $71,000 after purchasing an additional 8,191 shares during the period. Millennium Management LLC bought a new stake in Conformis during the 2nd quarter worth about $160,000. Finally, Avidian Wealth Solutions LLC lifted its position in Conformis by 84.8% during the 1st quarter. Avidian Wealth Solutions LLC now owns 509,968 shares of the medical instruments supplier’s stock valued at $318,000 after purchasing an additional 234,000 shares during the period. Institutional investors own 43.72% of the company’s stock.

Conformis Company Profile

(Get Rating)

Conformis, Inc, a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products.

See Also

Receive News & Ratings for Conformis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conformis and related companies with MarketBeat.com's FREE daily email newsletter.